Fluifort (Carbocysteine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Fluifort (Carbocysteine)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Fluifort (Carbocysteine)

Quick Facts

Property Description
Active Ingredient Carbocysteine (S-Carboxymethyl-L-cysteine)
Form Oral Solution (Syrup), Capsules, and Granules for Solution
Pharmacological Class Mucoactive Agent / Mucolytic
Common Purpose Reducing the viscosity and facilitating the clearance of thick respiratory mucus
Origin Synthetic derivative of the amino acid L-cysteine

What is Fluifort (Carbocysteine) and its General Classification?

Fluifort is a pharmaceutical preparation whose active ingredient is Carbocysteine, classified as a mucoactive agent and mucolytic. This substance is categorized under the Anatomical Therapeutic Chemical (ATC) code R05CB03, belonging to the group of expectorants that modify the structure of mucus. As a single-ingredient product, it is administered via the oral route, typically available as a liquid oral solution (syrup) and as granules for solution packed in sachets. Fluifort is often characterized by its use of the Carbocysteine lysine salt monohydrate formulation, which enhances the drug’s solubility and bioavailability compared to the standard base form.

Carbocysteine: Composition, Origin, and Purpose

Carbocysteine, chemically known as S-Carboxymethyl-L-cysteine, is a synthetic derivative of the naturally occurring amino acid L-cysteine. Its core purpose is defined by its targeted fluidifying action on excessive or viscous mucus within the airways. Carbocysteine acts as a mucoregulatory agent, helping to chemically reduce the thickness and stickiness (viscosity) of phlegm and promote effective mucus clearance. Beyond this primary role, the compound is used in scenarios involving persistent, wet cough accompanied by chest congestion, as it also exerts anti-inflammatory and antioxidant effects that may benefit overall respiratory health.

Advertisements

What side effects are possible with Fluifort (Carbocysteine)?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of Carbocysteine into System-Organ Classes (SOCs), with the most frequently documented effects pertaining to Gastrointestinal Disorders and Immune System/Skin and Subcutaneous Tissue Disorders.

Adverse Reactions and Frequency Classification

Adverse reactions are formally categorized according to their rate of occurrence as defined in regulatory texts. Those classified as rare (ge1/10,000 to <1/1,000) may include diarrhoea and nausea. Reactions such as abdominal pain and general allergic skin reactions (pruritus, urticaria, rash) are classified as very rare (<1/10,000).

The frequency is not known for several more serious reactions, including anaphylactic reactions, gastrointestinal bleeding, vomiting, and severe cutaneous adverse reactions (SCARs), such as Stevens–Johnson syndrome and Erythema multiforme. The explicit listing of these reactions in regulatory documents establishes the most severe, though infrequent, risks associated with the medicine.

Safety Restrictions and Special Populations

Carbocysteine is subject to specific safety constraints. The presence of active peptic ulceration constitutes a formal contraindication for use. Caution is recommended for older adults and individuals who have a history of gastroduodenal ulcers. Furthermore, the medicine is generally not recommended during the first trimester of pregnancy or while breastfeeding due to insufficient data. Administration-agnostic safety notes advise caution when the product is used concurrently with other medications known to cause gastrointestinal bleeding.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official overdose information documented by government regulatory authorities.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations The most likely clinical findings associated with the ingestion of a dose exceeding the recommended amount are Gastrointestinal disturbance, including nausea, vomiting, diarrhea, and gastralgia (stomach pain).
Physiological systems affected The primary physiological system affected by the direct manifestations of overdosage is the Gastrointestinal system.
Emergency-response statements Management involves symptomatic and supportive therapy and may include the procedure of gastric lavage followed by a period of clinical observation.
When immediate medical help is required Consult a doctor or go to the nearest hospital immediately if severe signs are observed, such as symptoms indicative of bleeding from the stomach or intestine (e.g., blood in vomit or black, tarry stools).

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification The need for urgent help is triggered by the potential for severe adverse reactions, specifically Gastrointestinal bleeding.
Overdose-context constraints No specific antidote is documented for Carbocysteine overdosage.

Resulting Overdose Structure

Official regulatory statements confirm that the Gastrointestinal disturbance profile defines the immediate clinical presentation of an overdose. Treatment is strictly limited to symptomatic and supportive therapy, reflecting the confirmed absence of a specific pharmacological antidote. Urgent medical attention is mandated when signs of a severe complication, such as gastrointestinal bleeding, are present.

Advertisements

Therapeutic Uses of Fluifort (Carbocysteine)

The use of Fluifort (Carbocysteine) is applied in contexts marked by symptoms related to physical discomfort due to thick phlegm in the airways. This therapeutic agent is commonly used across domains where additional symptomatic support is needed to address the symptoms that interfere with daily functioning.


Key Therapeutic Applications

Fluifort is considered relevant for managing symptoms in conditions characterized by episodic or fluctuating manifestations. The medication is utilized for the symptomatic management of chronic conditions, including Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis, as well as acute episodes like Acute Bronchitis. It primarily targets symptom clusters that may become intense or disruptive, arising from symptoms that create noticeable physiological strain.

The main patient benefit is associated with easing the symptoms that arise from these thick secretions, which helps the patient to expectorate the phlegm more easily. It is applied in clinical settings that involve acute or unstable symptom patterns, such as periods of heightened chest congestion.

“The therapeutic benefit of this medication is linked to its ability to support the patient’s capacity to cope more steadily with symptom fluctuations caused by thick mucus.”

Quick Fact: Symptomatic Support for Difficulty Clearing Phlegm
Symptom Type: Difficulty Expectoration and Symptom-Driven Cough.
Use Context: Applied in chronic obstructive airway diseases and acute bronchopulmonary episodes.
Patient Benefit: Contributes to easing the overall symptom load and supports maintenance of functional stability.
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Fluifort (Carbocysteine)?

The eligibility profile for Carbocysteine is defined by specific exclusions, restrictions, and age guidelines documented in official regulatory labeling.

Category Regulatory Status
Contraindicated Populations Active peptic ulceration or known hypersensitivity to Carbocysteine or excipients. Children under two years of age (for syrup formulations).
Conditional Use Caution is recommended in the elderly, in patients with a history of gastroduodenal ulcers, and when taking concomitant medications that may cause gastrointestinal bleeding.
Age-Group Rules Contraindicated in children under 2 years. Use is established in adults and children aged 2 years and above, using appropriate formulations.
Pregnancy and Lactation Use is not recommended during pregnancy (especially the first trimester) or breastfeeding due to insufficient available safety data.
Other Restrictions Patients with rare hereditary metabolic disorders (e.g., fructose intolerance, lactase deficiency) are excluded from using specific excipient-containing products.

The overall regulatory structure establishes non-eligibility through absolute contraindications and defines limited or conditional use for specific populations, such as the elderly, where special caution is advised.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Carbocysteine is primarily defined by pharmacodynamic restrictions and constraints related to managing the risk of adverse effects when co-administered with certain drug classes.

Contraindicated and Restricted Combinations

Co-administration with antitussive medicinal products (cough suppressants) is restricted by national regulatory agencies. This constraint is in place because antitussive agents may inhibit the cough reflex necessary to clear the increased, liquefied bronchial secretions. Combination with medicines used to dry secretions, such as certain anticholinergics, is also restricted as it may oppose the fluidifying action of Carbocysteine.

Officially Documented Drug Interactions

Interacting Class Official Interaction Description/Outcome
Antibiotic Agents (e.g., Amoxicillin) Documented to enhance the concentration and penetration of select antibiotics into bronchial secretions (a change in local tissue exposure).
NSAIDs, Antiplatelet Agents, Oral Corticosteroids Caution is advised due to an officially documented additive risk of gastrointestinal bleeding or ulceration.

Other Interaction Considerations

Official labeling does not typically document systemic metabolic (CYP) or transporter-mediated interactions. However, some liquid formulations of Carbocysteine contain ethanol (alcohol) as an excipient. This requires consideration for specific populations, including children and patients with liver disease or those advised to avoid alcohol intake.

Advertisements

Mechanism of Action

Breaking Down Mucus Structure (Mucolysis)

This mechanism targets the mucin glycoproteins by chemically cleaving the disulfide bonds that link them together, which immediately reduces the overall viscosity and elasticity of the existing thick mucus. This chemical interaction is necessary for the rapid physical fluidification of secretions and is the prerequisite for subsequent clearance.

Regulating New Mucus Quality (Muco-regulation)

Carbocysteine modulates the activity of key cellular enzymes, such as sialyltransferase, in mucus-secreting cells. This shifts the synthesis ratio toward less-viscous sialomucins and away from sticky fucomucins. The mechanism influences the quality of future secretions, contributing to the sustained regulation of mucus layer rheology.

Enhancing Secretion Clearance (Physiological Effect)

The combined mucoactive effect of altered rheology and controlled secretion quality facilitates the improved function of the mucociliary escalator system. The enhanced efficiency of the system increases the rate of secretion clearance.

Providing Antioxidant and Cytoprotection

The drug also acts as an antioxidant by scavenging Reactive Oxygen Species (ROS) and suppresses inflammatory signaling pathways (like NF-kappaB) within the respiratory epithelium. This supplementary action reduces oxidative stress and dampens localized inflammatory signaling cascades that influence epithelial cell activity.

Advertisements

Dosage and Administration Information

Official Administration Regimens

The use of Carbocysteine, the active ingredient in Fluifort, is restricted to the oral route of administration. The medicine is supplied as capsules, syrup, or granules for oral solution, and dosing guidelines vary based on the specific formulation, but adhere to a standard initial-to-maintenance pattern for adults.

Administration Scope General Instruction
Adult Initial Dose 2250 mg total daily dose (Carbocysteine base equivalent).
Dosing Frequency The initial adult dose is divided into 3 times per day. The maintenance dose is typically taken 3 or 4 times per day.
Maintenance Dose 1500 mg total daily dose, administered when a satisfactory response is obtained following the initial course.
Lysine Salt Regimen An alternative dose of 2.7 g of the lysine salt formulation is typically administered once daily (e.g., in a sachet).
Timing with Food The medicine can be taken with or without food.

Age-Specific and Procedural Instructions

Administration is contraindicated for children under 2 years of age; a specific liquid posology, typically in divided doses (e.g., three to four times daily), is defined for children 2 to 12 years. The capsule formulation is not generally recommended for children. For liquid forms, an accurate measuring device (such as a spoon or syringe) must be used to ensure correct dosing, and the bottle should be shaken before use. If a dose is missed, it should be taken when remembered, but skipped if the next dose is due within 2 hours, with strict instruction never to take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluifort (Carbocysteine)

Evidence for Long-Term Management in Chronic Conditions

The research base for Carbocysteine in chronic conditions, such as Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, primarily consists of long-term randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These studies were used in research exploring how symptoms change over time in conditions presenting with cycles of stability and flare-ups, by examining patient outcomes over many months.

Researchers primarily monitored the annual rate of acute exacerbations (periods of heightened symptom activity). They also examined patient-reported outcomes describing perceived discomfort and overall Quality of Life using standardized questionnaires. Some studies reported measurements indicating a lower frequency of exacerbations in certain chronic populations compared to a control group. Studies also reported changes in Quality of Life scores measured in the observed populations receiving the study drug compared to the control group.

Evidence for Symptomatic Relief in Acute Respiratory Infections

Research has explored the use of Carbocysteine in symptomatic management for acute upper and lower respiratory tract infections, often through short-term controlled trials and subsequent systematic reviews. These studies were relevant in trials assessing short-term or episodic symptom patterns, focusing on outcomes describing episodic or acute changes.

Studies examined how symptoms, such as the duration and severity of cough and phlegm production, were measured in the observed populations compared to a control group or placebo. Research monitored outcomes related to the physical properties of mucus and the movement of secretions in the airways (mucociliary clearance) during the study period. While studies report how symptom patterns were measured in the observed populations, some reviews noted that the reported changes were sometimes of limited clinical relevance when compared to the natural course of the infection.

Evidence Gaps and Areas of Uncertainty

A significant finding across the evidence landscape is that subgroup findings are uncertain. The patterns observed in patients with mild-to-moderate disease were often reported as being inconsistent when compared to those with more severe forms of the condition. Reports indicated that lung function measures (like FEV1) were generally similar between study and control groups over the course of the trials. Furthermore, comparative evidence against other mucoactive agents is limited, though this research contributes to the broader evidence landscape without determining individual response.

Key Studies & References

  1. Carbocisteine Teva 375mg capsules, hard - Summary of Product Characteristics (SmPC)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fluifort (Carbocysteine) (FAQ)

Q: How does Fluifort relate to similar medicines used for coughs or mucus?

A: Carbocysteine is classified as a mucolytic, meaning it chemically thins secretions. Official documents restrict its use alongside certain cough suppressants (antitussives). This is because antitussives can inhibit the natural cough reflex needed to clear the mucus that Carbocysteine has thinned, which is the intended goal of the medicine.

Q: Is there a generic version of Carbocysteine available?

A: Carbocysteine is the active pharmaceutical ingredient (API) found in Fluifort. It is a widely available substance that may be sold under its generic name or under various other brand names in different countries.

Q: Does Fluifort make you drowsy or affect your ability to concentrate?

A: Official product information indicates that the medicine has a negligible influence on the ability to drive and use heavy machinery. Drowsiness or effects on concentration are not typically listed among the common adverse reactions reported in regulatory documents.

Q: How long does it usually take for Fluifort to start having an effect?

A: According to authoritative information, the medicine begins its chemical action to break down mucus structure immediately after it is administered. However, patients may not notice an immediate improvement in their respiratory symptoms, as full relief can take more time.

Q: What is the typical duration of use for Fluifort?

A: The appropriate duration of use is generally determined by the specific condition. While the medicine is used for short-term symptomatic relief in acute illnesses, studies also support its use for long-term management (e.g., three months or more) in chronic respiratory conditions.

Q: Are there any specific foods or drinks that should be avoided while using Fluifort?

A: Official administration guidelines state that the medicine can be taken with or without food. Beyond the caution regarding alcohol content in some liquid excipients, regulatory documents do not list explicit warnings about avoiding specific non-alcohol foods or drinks.

Q: Does Fluifort interact with common pain relievers like ibuprofen or paracetamol?

A: Official warnings document an additive risk of gastrointestinal bleeding when Carbocysteine is used with certain drug classes like NSAIDs (e.g., ibuprofen). Paracetamol (acetaminophen) is not explicitly listed in this warning.

Q: Can Fluifort be taken by someone who has kidney problems?

A: Regulatory documents define the use of Carbocysteine as conditional, requiring caution in patients with a history of or existing kidney issues. Use is generally avoided in cases of severe kidney impairment.

Q: What are the most common reported side effects of Fluifort?

A: Based on regulatory reporting, the most commonly experienced adverse reactions are related to the gastrointestinal system. These typically include diarrhoea and nausea, which have been reported to affect up to 1 in 10 people.

Q: Is Carbocysteine the same as acetylcysteine?

A: Carbocysteine is defined as a synthetic derivative of the amino acid L-cysteine. Both Carbocysteine and Acetylcysteine are distinct compounds, but they belong to the same pharmacological class and work by a similar pharmacological action to thin mucus.

Q: Does Fluifort have a risk of becoming habit-forming?

A: Official regulatory reviews have found no reports or warnings to indicate that the active ingredient, Carbocysteine, has any risk of being habit-forming or leading to dependence.

Q: How does Fluifort affect mucus compared to just drinking water?

A: Carbocysteine works via a direct pharmacological action to reduce mucus viscosity and elasticity. This is a fundamental, pharmacological process that is distinct from the general thinning achieved through simple hydration (drinking water).

Q: Does Fluifort affect the effectiveness of oral contraceptives?

A: Official drug interaction lists for Carbocysteine generally do not document an interaction that would compromise the effectiveness of oral contraceptives (hormonal birth control).

Q: What is known about the evidence quality for Carbocysteine research?

A: The evidence base includes various Randomized Controlled Trials and Meta-analyses. However, official reviews have noted that some reported changes are of limited clinical relevance, and results for different patient subgroups can be inconsistent or uncertain.

Q: Are there any contraindications related to liver function?

A: Official regulatory documents define the use of Carbocysteine as conditional, requiring caution in patients with a history of or existing liver problems. This warning is often emphasized for liquid formulations that contain ethanol (alcohol) as an excipient.

Q: What common supplements or vitamins might interact with Fluifort?

A: Official guidance states that disclosure of all herbal remedies, vitamins, or supplements to a healthcare provider is required, as safety data is often insufficient for these combinations.

Q: Is it normal to notice a change in the color or consistency of mucus while using Fluifort?

A: The medicine is intended to reduce the viscosity and elasticity of thick mucus to facilitate clearance. Noticing a physical change in the consistency of secretions—making them thinner and less sticky—is consistent with the intended pharmacological effect.

Q: Does Fluifort contain lactose or gluten?

A: The capsule formulation of Carbocysteine is documented in patient information leaflets to contain lactose. Checking the full excipient list is required for patients with known allergies or hereditary metabolic disorders.

Q: Are there any restrictions on driving or operating machinery while taking Fluifort?

A: Official regulatory documentation states that the medicine has a negligible influence on the ability to drive and operate machinery.

Q: Are there documented cases of Fluifort overdose?

A: Documented symptoms of Carbocysteine overdose primarily include gastrointestinal disturbance (stomach upset). Overdose may also increase the risk of more serious issues like gastrointestinal bleeding.

Q: Why do some regulatory bodies categorize Carbocysteine differently?

A: Carbocysteine is officially classified internationally as a mucoactive agent/mucolytic. Minor variations in categorization may occur based on the specific salt formulation used (e.g., lysine salt) or differences in local country policies on prescribing status (prescription versus over-the-counter).

Q: Is there any research on Fluifort's effectiveness in pediatric populations?

A: Regulatory approval confirms that Carbocysteine is suitable for use in children aged 2 years and above. This approval means that health authorities have found the product suitable for use in this specific age group.

Advertisements

How should Fluifort (Carbocysteine) be stored and disposed of?

Official Storage Requirements

Regulatory documentation specifies strict conditions for storing Fluifort (carbocysteine) to maintain its stability and effectiveness. The medicine must be stored at a temperature below 25 C and should be protected from both light and moisture. It is required that the product remain in its original container until use. Additionally, all medicinal products must be kept out of the sight and reach of children.

Handling and Disposal

Fluifort must not be used beyond the expiry date (EXP) printed on the packaging. For disposal, the unused medicinal product or waste material must be discarded in accordance with local requirements. Official instructions prohibit throwing the medicine away via wastewater or household waste, requiring return through designated collection systems, such as a pharmacy take-back scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluifort (Carbocysteine) found in:

A-Z Index: